Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early intravenous esmolol after primary PCI for STEMI
ChiCTR2100045516Phase 4Recruiting
- Sponsor
- Xinxiang Central Hospital
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esmolol in myocardial infarction (MI) (2 arms), sponsored by Xinxiang Central Hospital. Primary endpoints: CMR myocardial infarction size (%) and Major adverse cardiac and cerebrovascular events. Started Jun 2021; status: recruiting.
02
Drugs
esmolol
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2100045516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045516.